Design, Setting, and Participants: We used AI and statistical analyses to identify progression-related genes in a microarray dataset (n=66 tumors, n=2,800 genes). The AIselected genes were then investigated in a second cohort (n=262 tumors) using immunohistochemistry.
A bstract
Background: New methods to identify bladder cancer progression are required. Geneexpression microarrays can reveal insights into disease biology and identify novel biomarkers. However, these experiments produce large datasets that are hard to interpret.
O bjective: To develop a novel method of microarray analysis combining two forms of artificial intelligence (AI): NeuroFuzzy Modeling (NFM) and Artificial Neural Networks (ANN). To validate this in a bladder cancer cohort.
Design, Setting, and Participants: We used AI and statistical analyses to identify progression-related genes in a microarray dataset (n=66 tumors, n=2,800 genes). The AIselected genes were then investigated in a second cohort (n=262 tumors) using immunohistochemistry.
Measurements:
We compared the accuracy of AI and statistical approaches to identify tumor progression.
Results and limitations: AI identified 11 progression-associated genes (OR=0.70 (95% CI=0.56-0.87) p=0.0004) and these were more discriminate than genes chosen using statistical analyses (OR=1.24 (95% CI=0.96-1.60) p=0.09). The expression of 6 AIselected genes (LIG3, Fas, KRT18, ICAM1, DSG2 and BRCA2) was determined using commercial antibodies and successfully identified tumor progression (Concordance
Introduction
The care of patients with Urothelial Carcinoma of the bladder (UCC) could be significantly improved if their tumor behavior was accurately identified at diagnosis.
Patients with non-progressive superficial disease could be spared endoscopic surveillance and BCG immunotherapy, whilst those at high progression risk could opt for early cystectomy. For invasive tumors the use of systemic chemotherapy could be rationalized to cases with highest progression risk. Tumor behavior can be hard to determine from histopathology alone. For example, the progression risk for non-muscle UCC varies between <1% and >50% [1, 2] . Furthermore, as stage and grade are often linked, when one is fixed (e.g. stage) the other performs poorly (e.g. grade) at identifying tumor progression. It is hoped that molecular knowledge will reveal an understanding of tumor biology that allows accurate phenotype identification.
As current biomarkers are insufficiently robust for clinical practice, microarrays have been used to identify new candidates [3] [4] . Microarray experiments reveal great insights into tumor biology but the cost and magnitude of these experiments prohibit large sample size analyses. Thus, microarray datasets have high dimensionality (large imbalance between gene number and sample size) that leads to analytical difficulties [5] [6] [7] . Successful analysis requires the identification of genes related to tumor-class and the removal of non-contributing variables. Poor analysis leads to data over-fitting and irreproducible results [5] . Traditional analytical techniques, such as hierarchical clustering, assume biological linearity and use statistical proximity to infer class-gene relationships (so called 'feature selection'). They perform poorly in datasets contaminated with variable noise. Artificial intelligence (AI) is a machine learning approach without these prerequisites. Various AI techniques exist [8] and successful microarray analysis has been reported using artificial neural networks (ANN) [9] [10] and support vector machines (SVMs) [11, 12] in non-urothelial malignancies. However, the hidden working layer of an ANN prevents model understanding and hinders its acceptance by the scientific community [13] , whilst SVMs still use proximity to infer class-gene associations and function poorly with respect to interpretability [14] .
An alternative form of AI is the neurofuzzy model (NFM). This has a similar design to an ANN, but uses a transparent fuzzy logic internal structure [8] . This transparency allows model understanding, parameter interrogation and can facilitate the inclusion of priori qualitative knowledge. When used to identify tumor progression we have previously found that NFM is accurate, reproducible and appears superior to regression based classifications [15, 16] . We hypothesized that NFM could improve microarray analysis and identify prognostic gene panels that could accurately predict the behavior of UCC.
To test this hypothesis we examined a previously reported non-muscle invasive UCC microarray dataset to find genes associated with progression to invasion. Genes associated with progression were then tested in a new larger UCC cohort using immunohistochemistry.
M aterials and methods

Patients and Tumors
We studied two patient populations (Table 1) . For microarray analysis we used 66 tumors from 34 patients, treated at the Ludwig Maximilian University, Germany (detailed in [17] ). Progression to muscle invasion occurred in 10/34 patients (29%) and the median follow up was 43 months. For immunohistochemical analysis we studied 262 tumors from separate consecutive patients treated at the University of Regensburg, Germany. We created a tissue microarray (TMA) using paraffin embedded formalin fixed tissues with 2 cores per cases (1.2mm) [18] . Progression information was available for 182/262 (69.5%) patients and muscle invasion or new metastases occurred in 49 patients (26.9%). The median follow up was 89 months (range 2-154). No patients were in both UCC populations. Normal urothelium from patients with benign prostatic hyperplasia (n=20) and co-existing UCC (n=15) was also analyzed. Institutional review board approval was obtained from both institutions prior to study commencement.
RNA Extraction and Gene Expression Microarray Analysis
The microarray (metg001A) contained 2,800 genes (6,117 probesets) annotated by the GoldenPath assembly. The microarray experiments and data processing are reported in detail elsewhere [17] .
Artificial Intelligence F eature Selection
To analyze the microarray data we used a 'Committee of models' approach that assimilated findings from each individual AI model (Figure 1 ), as we wanted to determine gene-progression relationships that were not dependent upon one AI structure.
We initially performed a dimension reduction using Pearson's coefficient to identify the 200 genes most associated with progression. These selected genes were then analyzed using iterative ANN and NFM models in two structures, which we termed 'Selectivity' and 'Averaging' (Figure 1 ). These structures enable simultaneous analysis of all genes, rather than a 'Leave-One-Out' approach. ANNs were produced within Statistica (Version 7, StatSoft Ltd, Bedford, UK). NFMs were produced within Matlab (Version 6.5 www.mathworks.com) and progression predictions performed using an in-house software suite [19, 20] . The data were divided into 90% for training (60% was learning and 30% for validation) and 10% for testing. Ensembling and cross validation were used to maximize data [21] . 
Statistical Analysis
All analyses were two tailed and carried out using SPSS (version 14, SPSS Inc).
Categorical variables were compared using the 2 test and continuous variables with a T test. Disease progression was defined when a non-muscle invasive tumor became invasive or a muscle invasive tumor developed metastases. Progression-specific survival probability following tumor resection was analyzed using the Kaplan-Meier method and Log rank test. Patients without progression were censored when they were last reviewed or when they died of other causes. The concordance index was calculated as reported [23] . A P value of <0.05 was interpreted as statistically significant. Cox regression multivariate analysis was used to compare the prognostic value of the various gene panels with clinicopathological parameters.
Results
Dimension reduction
We aimed to produce a prognostic gene panel of around 11 members to allow comparison with the Original panel chosen by statistical methods. Analysis of predictive ANN and NFM models with increments of 1 to 200 members revealed this was feasible (Figure 2 ).
For NFM, the modeling error with 11 genes (RMS=0.135) was similar to that for more than 157 genes (both concordance index=1.0). For ANN the error did not change until more than 140 gene inputs were used (RMS = 0.37 for 11 genes), and was larger than the equivalent for NFM.
Gene Ranking and Comparison of F eature Selection Panels
We ranked the 200 genes according to their average score from the various AI models (Table 2) For example, LIG3 and ICAM1 were associated with tumor stage and grade (χ 2 p<0.05) (Table 3) , when compared to tumors with normal expression. However, when expression of individual proteins with respect to tumor behavior was analyzed, few significant relationships were present. Only abnormal TNFRSF6 expression was significantly associated with tumor progression (Log rank p=0.003).
We then analyzed the 6 proteins together as a Committee panel using only superficial tumors (n=134). Each tumor was scored according to the number of proteins with abnormal staining and this was expressed as a percentage of the total number successfully immunostained for that sample. Only samples with ≥4 stained proteins were evaluated.
When progression was analyzed with respect to this score, significantly worse outcomes were present in tumors with higher than lower scores ( Figure 4b ). As with its use in the first tumor cohort, the panel's discriminating ability was maximal at its mean content (Concordance index =0.66, Log rank p=0.02 for 40% and p=0.01 for 50% 
Discussion
Here we have used AI to examine the relationship between gene expression and progression. To evaluate this approach, rather than specific model designs, we used a
Committee of models to merge gene rankings from individual models and structures. AI can identify complex relationships within non-linear data contaminated by variable noise and as such, can outperform statistical regression [8, 24] . AI modeling is a generic process and these methods could be applied to re-interrogate microarray datasets for prognostic and functional data.
Our approach reduced 200 genes to 11 with minimal deterioration in progression identification. The highest ranked genes appeared better at predicting tumor outcome than those selected using traditional analysis and pathological criteria. The fuzzy logic layer of our Committee NFM is shown in Figure 3b . This rule-base consists of parallel rules in which the fuzzy logic component can be visualized. In rule 1 (top line), high KRT18 in combination with low DSG2 and TNFRSF6 expression leads to rapid tumor progression (final box). This supports known carcinogenic functions of these genes as KRT18 is an oncogene and the others are tumor suppressors [25] . One can also see that the discriminatory effects in TP53BP2 are less apparent than for other genes (TP53BP2 was ranked 11th, Table 2 ).
The ability of AI to determine non-linear relationships is demonstrated in our results. Of and ARHE. Fas is important for apoptosis induction and decreased expression is associated with advanced bladder cancer stage, grade and progression [26] . TP53BP2
(also 'Apoptosis stimulating protein of p53 2' (ASPP2)) plays a key role in apoptosis induction through the activation of p53. Reduced TP53BP2 expression abrogates the onset of apoptosis in cancer, but has not been reported in UCC. Tumor invasion is represented by reduced cellular adhesion (ICAM1 and DSG2) and cytoskeletal reorganization through increased KRT18 and reduced ARHE expression. DSG2 is a cellular adhesion molecule whose loss reduces adhesion, increases invasion and speeds tumor progression [27] . ICAM1 is also an intercellular adhesion molecule and is frequently epigenetically silenced in UCC (>70%) [28] . KRT18 is a cytokeratin known to be expressed in the umbrella layer of urothelium whose expression increases with urothelial carcinogenesis [25] . ARHE (also 'Rho family GTPase 3' (RND3)) is a Rho signal transduction member with roles in many cellular processes (cytoskeleton organization, membrane trafficking, cell growth and apoptosis) [29] , whose loss is reported in prostate cancer. Deranged DNA repair is represented by BRCA2 and LIG3 [30] .Whilst neither is directly linked with bladder carcinogenesis, it is possible that loss of both is required for carcinogenic alteration. BRCA2-deficient cells have reduced DNA ligation capacity which can be reversed by LIG3 administration [30] .
Conclusion
AI can analyze microarray datasets in a complementary manner to statistical analyses.
Both methods use different techniques of inference to determine gene-phenotype associations and thus identify distinct prognostic gene signatures that are equally valid.
We have identified a new prognostic gene signature in UCC, whose members reflect a variety of carcinogenic pathways. This signature requires validation in new tumor cohorts to assess its ability to identify progression in non-muscle invasive bladder cancers. Unknown function 11 TP53BP2 p53 binding protein 2 (ASPP2)
Cell cycle/ apoptosis regulation / signal transduction Genes shown in bold were analysed by immunohistochemistry 
